|
|
|
|
| |
Synergo Adjuvant Treatment - cumulative experience until 2006
As is often the case with the launching and implementing a new medical technology,
the majority of the patients referred for Synergo
prophylactic treatment were the most difficult ones, who had exhausted all
possibilities for alternative treatments.
The High Risk patients (25) had an average of 5.3 occurrences prior to being
referred to Synergo. They had an average of only 210 days between TURs in
the previous 2 years prior to their Synergo treatment, i.e., a disease free
interval of only a few months.
The average disease free interval for the all population of the recurring patients was 235 days
Herein we report our experience with Synergo adjuvant treatment given to 131
patients at the following centers:
| Italy: |
HSR Hospital, Milan; University Policlinic Hospital, Palermo; IEO hospital, Milan; Galliera Hospital, Genoa
Treviglio Hosptial, Treviglio; Magenta Hospital, Magenta; Humanitas Gavazzeni, Bergamo
|
| Israel: |
Bnai Zion Hospital, Haifa; Wolfson Medical Center, Holon;
Rabin Medical Center, Belinson Campus, Petah-Tikva; Hadassah Medical Center, Jerusalem; Meir Medical Centre, Kefar-Saba;
Carmel Hospital, Haifa
|
| Germany: |
Muenchen-Harlaching (Krankenhaus), Munich; City Hospital, Offenbach
|
| The Netherlands: |
UMC St Radboud, Nijmegen; Academic Hospital, Maastricht
|
| Austria: |
Clinic Innsbruck
|
| France: |
Hôpital d’instruction des armées du Val de Grâce, Paris;
Tenon Hospital, Paris
|
|
|
Patients' characteristics:
|
Age:
|
Mean: 67
|
Range: 32-98
|
|
Gender:
|
105 Males (80%)
|
26 Females (20%)
|
|
High-risk:
|
63%
|
|
|
Intermediate risk:
|
37%
|
|
| The High Risk patients (83)
had an average of 3.4 occurrences prior to being
referred to Synergo. |
| The Interediate Risk patients (48)
had an average of 3.2 occurrences prior to being reffered to Synergo.
The average disease-free interval for this group was 362 days.
|
Number of patients with 3 or more recurrences in previous 24 months:
26 (19.8%)
(high recurrence)
|
Number of patients who had previously undergone BCG therapy :
37 (28%)
|
Number of patients who had previously
undergone instillations : 73 (56%)
|
Results
| 1. |
The results for the 131 prophylactic patients are:
All patients: 28 recurred (20.0%)
High Risk patients: 21 recurred (25%) with a 2-year K-M estimated recurrence rate of 40%
Intermediate Risk patients: 7 recurred (14.5%) with 2-year K-M estimated
recurrence rate of 31%.
|
| 2. |
Progression to T>T1 was observed in 2 patients only after a mean follow-up
of 13 months (range 2-66months)
|
| 3. |
Side effects:
Mild pain during session, dysuria, hematuria and frequency during the first day after treatment.
All patients resumed normal daily activity after each treatment.
|
|
|
| |
Home |
